Peachtree Radiation Oncology

Dr. Adam W. Nowlan

Claim this profile

Piedmont Hospital

Studies Brain Tumor
Studies Breast Cancer
17 reported clinical trials
49 drugs studied

Area of expertise

1

Brain Tumor

Adam W. Nowlan has run 7 trials for Brain Tumor. Some of their research focus areas include:

Stage IV
IDH positive
IDH negative
2

Breast Cancer

Adam W. Nowlan has run 6 trials for Breast Cancer. Some of their research focus areas include:

HER2 positive
ER positive
HER2 negative

Affiliated Hospitals

Image of trial facility.

Piedmont Hospital

Image of trial facility.

Piedmont Fayette Hospital

Clinical Trials Adam W. Nowlan is currently running

Image of trial facility.

Stereotactic Radiosurgery vs. HA-WBRT + Memantine

for Brain Cancer

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hippocampus is a brain structure that is important for memory. Memantine is a drug that is given to help relieve symptoms that can be caused by WBRT, including problems with memory and other mental symptoms. Health Canada, the regulatory body that oversees the use of drugs in Canada, has not approved the sale or use of memantine in combination with WBRT to treat this kind of cancer, although they have allowed its use in this study.

Recruiting

2 awards

Phase 3

Image of trial facility.

Relugolix + Radiation

for Advanced-Stage Prostate Cancer

This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.

Recruiting

0 awards

Phase 2

More about Adam W. Nowlan

Clinical Trial Related

6 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 8 Active Clinical Trials

Treatments Adam W. Nowlan has experience with

  • Radiation Therapy
  • Relugolix
  • Stereotactic Radiosurgery
  • Partial Breast Irradiation
  • Regional Nodal XRT
  • Chestwall XRT

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Adam W. Nowlan specialize in?

Is Adam W. Nowlan currently recruiting for clinical trials?

Are there any treatments that Adam W. Nowlan has studied deeply?

What is the best way to schedule an appointment with Adam W. Nowlan?

What is the office address of Adam W. Nowlan?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security